Bayer axes 6,100 jobs in wake of Schering deal

Germany's Bayer is axing 6,100 jobs as it integrates Schering into the fold. Half of those jobs are being eliminated in Europe with about 1,000 pink slips going out in the U.S. The cuts will hit 2,850 administrative posts, 1,400 R&D positions and 1,850 production jobs.

"We want to create an internationally successful pharmaceutical company with competitive cost structures," Bayer Chief Executive Werner Wenning said in a statement. "We said right from the start of the integration that job cuts would be necessary in order to achieve the synergy targets."

- check out Bayer's press release
- here's the AP report on the cutbacks

Related Articles:
Bayer Schering outlines global R&D restructuring. Report
Bayer outbids Merck KGaA for Schering. Report

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.